In 2011, ipilimumab was approved by the FDA(Food and Drug Administration) for the treatment of advanced melanoma, followed by the approval of pembrolizumab and nivolumab (both PD-1 inhibitors) in 2014, ushering in the era of immune checkpoint inhibitors. This evidence concerns the gene PDCD1 and melanoma.